TScan Therapeutics, Inc. (TCRX) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
TScan Therapeutics, Inc. (TCRX) Bundle
Enhance your investment choices with the TScan Therapeutics, Inc. (TCRX) DCF Calculator! Explore real financial data, adjust growth predictions and expenses, and instantly visualize how these changes affect the intrinsic value of TScan Therapeutics, Inc. (TCRX).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 1.1 | 10.1 | 13.5 | 21.0 | 31.0 | 45.6 | 67.2 | 98.9 | 145.7 |
| Revenue Growth, % | 0 | 0 | 834.65 | 33.47 | 55.52 | 47.25 | 47.25 | 47.25 | 47.25 | 47.25 |
| EBITDA | -13.7 | -25.0 | -45.3 | -59.9 | -80.1 | -18.6 | -27.4 | -40.3 | -59.4 | -87.4 |
| EBITDA, % | 100 | -2304.42 | -446.67 | -442.62 | -380.53 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | .5 | 1.2 | 3.3 | 5.1 | 5.4 | 18.4 | 27.0 | 39.8 | 58.6 | 86.3 |
| Depreciation, % | 100 | 113.36 | 32.82 | 37.95 | 25.47 | 59.25 | 59.25 | 59.25 | 59.25 | 59.25 |
| EBIT | -14.2 | -26.2 | -48.6 | -65.0 | -85.5 | -18.6 | -27.4 | -40.3 | -59.4 | -87.4 |
| EBIT, % | 100 | -2417.79 | -479.49 | -480.57 | -406 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 41.8 | 34.8 | 161.4 | 120.0 | 192.0 | 31.0 | 45.6 | 67.2 | 98.9 | 145.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | 6.2 | 9.1 | 13.4 | 19.8 | 29.1 |
| Account Receivables, % | 100 | 0 | 0 | 0 | 0 | 20 | 20 | 20 | 20 | 20 |
| Inventories | .0 | .0 | .0 | .0 | .0 | 6.2 | 9.1 | 13.4 | 19.8 | 29.1 |
| Inventories, % | 100 | 0 | 0 | 0 | 0 | 20 | 20 | 20 | 20 | 20 |
| Accounts Payable | 1.0 | 2.9 | 1.8 | 2.9 | 2.4 | 15.5 | 22.8 | 33.6 | 49.5 | 72.9 |
| Accounts Payable, % | 100 | 268.2 | 17.4 | 21.51 | 11.28 | 50.04 | 50.04 | 50.04 | 50.04 | 50.04 |
| Capital Expenditure | -1.2 | -4.2 | -9.9 | -4.2 | -3.1 | -15.1 | -22.3 | -32.8 | -48.3 | -71.2 |
| Capital Expenditure, % | 100 | -390.6 | -98.03 | -31.22 | -14.95 | -48.84 | -48.84 | -48.84 | -48.84 | -48.84 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -13.6 | -26.1 | -48.6 | -64.6 | -85.5 | -18.4 | -27.1 | -39.9 | -58.8 | -86.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -13.4 | -27.2 | -56.4 | -62.6 | -83.8 | -14.4 | -20.9 | -30.7 | -45.3 | -66.7 |
| WACC, % | 6.92 | 6.97 | 6.98 | 6.97 | 6.98 | 6.96 | 6.96 | 6.96 | 6.96 | 6.96 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -139.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -68 | |||||||||
| Terminal Value | -1,370 | |||||||||
| Present Terminal Value | -979 | |||||||||
| Enterprise Value | -1,118 | |||||||||
| Net Debt | -41 | |||||||||
| Equity Value | -1,077 | |||||||||
| Diluted Shares Outstanding, MM | 66 | |||||||||
| Equity Value Per Share | -16.41 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: TScan Therapeutics, Inc.'s (TCRX) financial data pre-filled to facilitate your analysis.
- Automatic DCF Outputs: The template automatically calculates Net Present Value (NPV) and intrinsic value for your convenience.
- Customizable and Professional: A sleek Excel model designed to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for assessing projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive TCRX Data: Pre-loaded with TScan Therapeutics’ historical performance metrics and future growth projections.
- Highly Customizable Variables: Modify assumptions on revenue growth, profit margins, discount rates, tax implications, and capital investments.
- Interactive Valuation Framework: Instantly recalculates Net Present Value (NPV) and intrinsic value based on your specified parameters.
- Multiple Scenario Analysis: Develop various forecasting scenarios to explore different valuation results.
- Intuitive User Interface: Designed for ease of use, catering to both industry experts and newcomers.
How It Works
- Download the Template: Gain immediate access to the Excel-based TScan Therapeutics, Inc. (TCRX) DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model will automatically refresh TScan’s intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial strategy.
Why Choose This Calculator?
- Accurate Data: Real TScan Therapeutics financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to match your projections.
- Time-Saving: Pre-built calculations eliminate the need to start from scratch.
- Professional-Grade Tool: Designed for investors, analysts, and consultants.
- User-Friendly: Intuitive layout and step-by-step instructions make it easy for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling TScan Therapeutics, Inc. (TCRX) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to TScan Therapeutics, Inc. (TCRX).
- Consultants: Provide clients with professional valuation insights on TScan Therapeutics, Inc. (TCRX) swiftly and accurately.
- Business Owners: Gain insights into how biotech companies like TScan Therapeutics, Inc. (TCRX) are valued to inform your own business strategy.
- Finance Students: Explore valuation techniques using real-world data and scenarios related to TScan Therapeutics, Inc. (TCRX).
What the Template Contains
- Preloaded TCRX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.